The current and future role of biomarkers in type 2 cytokine-mediated asthma management
- PMID: 28134501
- DOI: 10.1111/cea.12881
The current and future role of biomarkers in type 2 cytokine-mediated asthma management
Abstract
Assessment and management of asthma is complicated by the heterogeneous pathophysiological mechanisms that underlie its clinical presentation, which are not necessarily reflected in standardized management paradigms and which necessitate an individualized approach to treatment. This is particularly important with the emerging availability of a variety of targeted forms of therapy that may only be appropriate for use in particular patient subgroups. The identification of biomarkers can potentially aid diagnosis and inform prognosis, help guide treatment decisions and allow clinicians to predict and monitor response to treatment. Biomarkers for asthma have been identified from a variety of sources, including airway, exhaled breath and blood. Biomarkers from exhaled breath include fractional exhaled nitric oxide, measurement of which can help identify patients most likely to benefit from inhaled corticosteroids and targeted anti-immunoglobulin E therapy. Biomarkers measured in blood are relatively non-invasive and technically more straightforward than those measured from exhaled breath or directly from the airway. The most well established of these are the blood eosinophil count and serum periostin, both of which have demonstrated utility in identifying patients most likely to benefit from targeted anti-interleukin and anti-immunoglobulin E therapies, and in monitoring subsequent treatment response. For example, serum periostin appears to be a biomarker for responsiveness to inhaled corticosteroid therapy and may help identify patients as suitable candidates for anti-IL-13 treatment. The use of biomarkers can therefore potentially help avoid unnecessary morbidity from high-dose corticosteroid therapy and allow the most appropriate and cost-effective use of targeted therapies. Ongoing clinical trials are helping to further elucidate the role of established biomarkers in routine clinical practice, and a range of other circulating novel potential biomarkers are currently being investigated in the research setting.
© 2017 John Wiley & Sons Ltd.
Similar articles
-
Systemic and breath biomarkers for asthma: an update.Curr Opin Allergy Clin Immunol. 2020 Feb;20(1):71-79. doi: 10.1097/ACI.0000000000000599. Curr Opin Allergy Clin Immunol. 2020. PMID: 31652141 Review.
-
Utility of serum periostin in combination with exhaled nitric oxide in the management of asthma.Allergol Int. 2017 Jul;66(3):404-410. doi: 10.1016/j.alit.2017.02.003. Epub 2017 Feb 28. Allergol Int. 2017. PMID: 28256388 Review.
-
Can biomarkers help us hit targets in difficult-to-treat asthma?Respirology. 2017 Apr;22(3):430-442. doi: 10.1111/resp.13014. Epub 2017 Mar 1. Respirology. 2017. PMID: 28248008 Review.
-
Predicting asthma morbidity in children using proposed markers of Th2-type inflammation.Pediatr Allergy Immunol. 2015 Dec;26(8):772-9. doi: 10.1111/pai.12457. Epub 2015 Sep 28. Pediatr Allergy Immunol. 2015. PMID: 26266838
-
Novel biomarkers for asthma stratification and personalized therapy.Expert Rev Mol Diagn. 2015 Mar;15(3):415-30. doi: 10.1586/14737159.2015.988613. Epub 2014 Dec 5. Expert Rev Mol Diagn. 2015. PMID: 25479456 Review.
Cited by
-
Association of serum YKL-40 and DPP4 with T2-high asthma in Chinese adults.Medicine (Baltimore). 2024 Feb 9;103(6):e37169. doi: 10.1097/MD.0000000000037169. Medicine (Baltimore). 2024. PMID: 38335422 Free PMC article. Review.
-
Type-2 inflammation and lung function decline in chronic airway disease in the general population.Thorax. 2024 Mar 15;79(4):349-358. doi: 10.1136/thorax-2023-220972. Thorax. 2024. PMID: 38195642 Free PMC article.
-
Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study.Respir Res. 2023 Sep 28;24(1):235. doi: 10.1186/s12931-023-02539-7. Respir Res. 2023. PMID: 37770889 Free PMC article.
-
Reliability of Total Serum IgE Levels to Define Type 2 High and Low Asthma Phenotypes.J Clin Med. 2023 Aug 22;12(17):5447. doi: 10.3390/jcm12175447. J Clin Med. 2023. PMID: 37685515 Free PMC article.
-
Recovery of Breakthrough Asthma Attacks Treated With Oral Steroids While on Monoclonal Antibody Therapy: Protocol for a Prospective Observational Study (BOOST).JMIR Res Protoc. 2023 Jun 23;12:e46741. doi: 10.2196/46741. JMIR Res Protoc. 2023. PMID: 37351918 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical